You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CSF-1R inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Unresectable Intrahepatic Cholangiocarcinoma Trial in Baltimore (Durvalumab, SNDX-6352)

Active, not recruiting
  • Unresectable Intrahepatic Cholangiocarcinoma
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Jan 10, 2023

Sarcoma, Advanced Sarcoma, High Grade Sarcoma Trial in New York (DCC-3014, Avelumab)

Active, not recruiting
  • Sarcoma
  • +6 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 26, 2022

Pancreatic Cancer Trial in Baltimore (Cyclophosphamide, GVAX, Pembrolizumab)

Active, not recruiting
  • Pancreatic Cancer
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Jan 5, 2023

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Portland (Edicotinib, Pharmacokinetic Study)

Terminated
Has Results
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 1, 2021

Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer Trial (Q702, Pembrolizumab)

Not yet recruiting
  • Esophageal Cancer
  • +3 more
  • (no location specified)
Jun 27, 2022

Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer Trial in Lyon, Toulouse (Pexidartinib, Durvalumab)

Completed
  • Colorectal Cancer
  • +3 more
  • Lyon, France
  • +1 more
Sep 2, 2021

Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) Trial in Italy (NMS-03592088)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Chronic Myelomonocytic Leukemia (CMML)
  • Bergamo, BG, Italy
  • +4 more
Mar 23, 2021

Positron Emission Tomography, Alzheimer, Neurodegenerative Diseases Trial in Shanghai ([18F]CSF-23)

Recruiting
  • Positron Emission Tomography
  • +2 more
  • [18F]CSF-23
  • Shanghai, China
    Huashan Hospital
Nov 19, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

Objective Response Rate Trial in Wuhan (GM-CSF)

Recruiting
  • Objective Response Rate
  • Wuhan, Hubei, China
    Renmin Hospital of Wuhan University
Feb 25, 2023

Solid Tumor, Advanced Cancer, Metastatic Cancer Trial in Los Angeles, Chicago, Morristown (Q702)

Recruiting
  • Solid Tumor
  • +2 more
  • Los Angeles, California
  • +3 more
Jul 29, 2021

NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma Breast
  • Suzhou, China
    Second Affiliated Hospital of Soochow University
Oct 29, 2022

Malignant Ascites Trial (Serplulimab, Molgramostim, Hypofractionated radiotherapy/Sterotactic body radiotherapy)

Not yet recruiting
  • Malignant Ascites
  • (no location specified)
Aug 11, 2022

PD-1 Inhibitor, G-CSF Trial in Guangzhou (Camrelizumab, G-CSF)

Recruiting
  • PD-1 Inhibitor
  • G-CSF
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2022

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Advanced Refractory Solid Tumors Trial in China (Hypofractionated radiotherapy, PD-1 inhibitor, GM-CSF)

Recruiting
  • Advanced Refractory Solid Tumors
  • Hypofractionated radiotherapy
  • +3 more
  • Beijing, China
  • +15 more
Aug 8, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Dalpiciclib Isetionate Tablets, Camrelizumab
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel),

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
  • +3 more
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Sep 17, 2022

PraG With RANKL Inhibitor for Treatment of Advanced Multiple

Not yet recruiting
  • Metastatic Solid Tumor
  • Suzhou, Jiangsu, China
    The Second Affiliated Hospital of Soochow University
Aug 16, 2022

Granulocyte Colony-Stimulating Factor, PD-1 Inhibitor Trial in Guangzhou (PEG-rhG-CSF)

Recruiting
  • Granulocyte Colony-Stimulating Factor
  • PD-1 Inhibitor
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2022

Immunotherapy, Refractory Leukemia, Relapsed Adult AML Trial in Suzhou (Visilizumab)

Recruiting
  • Immunotherapy
  • +3 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 2, 2021

Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma Trial in Guangzhou (PD-1 inhibitor, PD-1

Recruiting
  • Classical Hodgkin Lymphoma
  • Refractory or Relapsed Classical Hodgkin Lymphoma
  • PD-1 inhibitor
  • PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
  • Guangzhou, Guangdong, China
  • +2 more
May 6, 2022

Peripheral T Cell Lymphoma Trial in Ann Arbor, Columbus, Madison (Nivolumab, cabiralizumab)

Active, not recruiting
Has Results
  • Peripheral T Cell Lymphoma
  • Ann Arbor, Michigan
  • +2 more
Aug 13, 2021